- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06011577
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD (RELIGHT)
February 15, 2024 updated by: Relmada Therapeutics, Inc.
A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder in patients with inadequate response to ongoing background antidepressant treatment.
Eligible patients will continue to take their background antidepressant therapy and be randomized in a 1:1 ratio to treatment with REL-1017 or placebo for a 4 week treatment period.
Study Type
Interventional
Enrollment (Estimated)
300
Phase
- Phase 3
Expanded Access
Available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical Director
- Phone Number: 786-638-7384
- Email: clinicaltrials@relmada.com
Study Locations
-
-
Alabama
-
Dothan, Alabama, United States, 36303
- Recruiting
- Relmada Site
-
Homewood, Alabama, United States, 35209
- Not yet recruiting
- Relmada Site
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022
- Active, not recruiting
- Relmada Site
-
-
California
-
Anaheim, California, United States, 92805
- Not yet recruiting
- Relmada Site
-
Culver City, California, United States, 90230
- Active, not recruiting
- Relmada Site
-
Lafayette, California, United States, 94549
- Active, not recruiting
- Relmada Site
-
Newport Beach, California, United States, 92660
- Active, not recruiting
- Relmada Site
-
Orange, California, United States, 92868
- Recruiting
- Relmada Site
-
Rancho Cucamonga, California, United States, 91730
- Not yet recruiting
- Relmada Site
-
Redlands, California, United States, 92374
- Active, not recruiting
- Relmada Site
-
Sherman Oaks, California, United States, 91403
- Recruiting
- Relmada Site
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- Recruiting
- Relmada Site
-
-
Florida
-
Brandon, Florida, United States, 33511
- Recruiting
- Relmada Site
-
Hialeah, Florida, United States, 33027
- Recruiting
- Relmada Site
-
Jacksonville, Florida, United States, 32256
- Active, not recruiting
- Relmada Site
-
Miami, Florida, United States, 33133
- Active, not recruiting
- Relmada Site
-
Miami, Florida, United States, 33174
- Active, not recruiting
- Relmada Site
-
Okeechobee, Florida, United States, 34972
- Active, not recruiting
- Relmada Site
-
Tampa, Florida, United States, 33607
- Active, not recruiting
- Relmada Site
-
Tampa, Florida, United States, 33614
- Active, not recruiting
- Relmada Site
-
-
Illinois
-
Chicago, Illinois, United States, 60604
- Active, not recruiting
- Relmada Site
-
Springfield, Illinois, United States, 62794
- Recruiting
- Relmada Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- Active, not recruiting
- Relmada Site
-
-
Minnesota
-
Mankato, Minnesota, United States, 56001
- Not yet recruiting
- Relmada Site
-
-
New Jersey
-
Toms River, New Jersey, United States, 08755
- Active, not recruiting
- Relmada Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Not yet recruiting
- Relmada Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Recruiting
- Relmada Site
-
Cedarhurst, New York, United States, 11516
- Active, not recruiting
- Relmada Site
-
New York, New York, United States, 10036
- Recruiting
- Relmada Site
-
-
Ohio
-
West Chester, Ohio, United States, 45069
- Active, not recruiting
- Relmada Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Not yet recruiting
- Relmada Site
-
-
Tennessee
-
Franklin, Tennessee, United States, 37067
- Recruiting
- Relmada Site
-
Memphis, Tennessee, United States, 38119
- Active, not recruiting
- Relmada Site
-
-
Texas
-
Austin, Texas, United States, 78712
- Not yet recruiting
- Relmada Site
-
Bellaire, Texas, United States, 77401
- Active, not recruiting
- Relmada Site
-
Friendswood, Texas, United States, 77546
- Active, not recruiting
- Relmada Site
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Relmada Site
-
Wichita Falls, Texas, United States, 76309
- Active, not recruiting
- Relmada Site
-
-
Utah
-
Clinton, Utah, United States, 84015
- Recruiting
- Relmada Site
-
Draper, Utah, United States, 84020
- Active, not recruiting
- Relmada Site
-
-
Vermont
-
Rutland, Vermont, United States, 05701
- Not yet recruiting
- Relmada Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Recruiting
- Relmada Site
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Relmada Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female outpatients, 18-65 years of age, inclusive.
- Currently meets DSM-5 criteria for MDD without psychotic features, based on the SCID-5-CT, with a current major depressive episode (MDE).
- Inadequate response to 1 to 3 adequate antidepressant treatments in the current MDE.
Exclusion Criteria:
- Psychiatric hospitalization during the current major depressive episode.
- History or presence of clinically significant health conditions which in the opinion of the Investigator would negatively impact the safety of the participant.
- Participants who, in the Investigator's judgment, are at significant risk for suicide.
- Pregnant or planning to become pregnant.
- Breast-feeding or planning to breast-feed.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: REL-1017 25 mg
During the double blind treatment period (28 days), participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT)
|
REL-1017 tablet
Other Names:
|
Placebo Comparator: Placebo
During the double blind treatment period (28 days), participants will take 1 tablet of placebo, orally, per day in addition to their ongoing antidepressant (ADT)
|
Placebo tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in MADRS Total Score From Baseline to Day 28
Time Frame: Day 28
|
The MADRS is a 10-item scale and items are scored between 0-6 points.
For each item, a score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity.
A maximum total score is 60 points.
|
Day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Marco Pappagallo, Relmada Therapeutics
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 17, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
August 21, 2023
First Submitted That Met QC Criteria
August 21, 2023
First Posted (Actual)
August 25, 2023
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REL-1017-304
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States